Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19013
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Malamou-Mitsi, V. | en |
dc.contributor.author | Crikoni, O. | en |
dc.contributor.author | Timotheadou, E. | en |
dc.contributor.author | Aravantinos, G. | en |
dc.contributor.author | Vrettou, E. | en |
dc.contributor.author | Agnantis, N. | en |
dc.contributor.author | Fountzilas, G. | en |
dc.date.accessioned | 2015-11-24T18:56:16Z | - |
dc.date.available | 2015-11-24T18:56:16Z | - |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19013 | - |
dc.rights | Default Licence | - |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | en |
dc.subject | Carboplatin/administration & dosage | en |
dc.subject | Cisplatin/administration & dosage | en |
dc.subject | Disease Progression | en |
dc.subject | Drug Administration Schedule | en |
dc.subject | Epithelial Cells/pathology | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Staging | en |
dc.subject | Ovarian Neoplasms/*drug therapy/*metabolism/pathology | en |
dc.subject | Paclitaxel/administration & dosage | en |
dc.subject | Proportional Hazards Models | en |
dc.subject | Proto-Oncogene Proteins c-bcl-2/*biosynthesis | en |
dc.subject | Receptor, erbB-2/*biosynthesis | en |
dc.subject | Tumor Suppressor Protein p53/*biosynthesis | en |
dc.title | Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer | en |
heal.type | journalArticle | - |
heal.type.en | Journal article | en |
heal.type.el | Άρθρο Περιοδικού | el |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17465257 | - |
heal.language | en | - |
heal.access | campus | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.publicationDate | 2007 | - |
heal.abstract | BACKGROUND: Several oncogenes and onco-suppressor genes have been implicated in epithelial ovarian carcinogenesis, but their clinical significance is not clear and conflicting data have been found in various studies. PATIENTS AND METHODS: The immunohistochemical expression of HER-2, p53 and Bcl-2 proteins was investigated in a cohort of 95 patients with advanced epithelial ovarian cancer (stages IIc-IV). These patients participated in a phase III randomized clinical trial and were treated either with paclitaxel/carboplatin, orpaclitaxel/carboplatin alternating with paclitaxel/cisplatin. RESULTS: Positive immunostaining for HER-2, p53 and Bcl-2 proteins was found in 18%, 70.5% and 69.5% of the cases, respectively. In multivariate analysis, older patients (< 63 vs. > or = 63 years, p < 0.001), worse grade (I-II vs. III, p = 0.04) and p53 expression (negative vs. positive, p = 0.002) were significant prognostic factors independently associated with survival. CONCLUSION: p53 status along with age and grade appear to be independent prognostic factors for survival in patients with epithelial ovarian cancer. | en |
heal.journalName | Anticancer Res | en |
heal.journalType | peer-reviewed | - |
heal.fullTextAvailability | TRUE | - |
Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Malamou-Mitsi-2007-prognostic significance of.pdf | 670.11 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License